Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma-Reference-Cited by-同舟云学术

Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma

Published:2024-09-04 Issue:1 Volume:24 Page:
ISSN:1591-9528
Container-title:Clinical and Experimental Medicine
language:en
Short-container-title:Clin Exp Med

Author:

Ma Ruixue,Zhang Qi,Liu Yang,Li Hujun,Chen Huimin,Zhang Qianqian,Qiao Jianlin,Qi Kunming,Shen Guifang,Sun Cai,Song Xuguang,Cao Jiang,Cheng Hai,Zhu Feng,Yan Zhiling,Sang Wei,Li Depeng,Sun Haiying,Zheng Junnian,Li Zhenyu,Xu Kailin,Chen Wei^ORCID

Funder

Suqian Key Laboratory of Hematology

Natural Science Foundation of Jiangsu Province

Development Fund of Affiliated Hospital of Xuzhou Medical University

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10238-024-01477-y.pdf

Reference29 articles.

1. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-Cell therapy in patients with relapsed or refractory multiple myeloma (cartitude-1): a phase 1b/2 open-label study. Lancet. 2021;398:314–24. https://doi.org/10.1016/S0140-6736(21)00933-8.

2. Raje N, Berdeja J, Lin Y, et al. Anti-Bcma car T-cell therapy Bb2121 in relapsed or refractory multiple myeloma. New Engl J Med. 2019;380:12. https://doi.org/10.1056/NEJMoa1817226.

3. Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705–16. https://doi.org/10.1056/NEJMoa2024850.

4. Xia J, Li H, Yan Z, et al. Anti-G protein-coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase II trial. J Clin Oncol. 2023;41:2583–93. https://doi.org/10.1200/jco.22.01824.

5. Wang Y, Cao J, Gu W, et al. Long-term follow-up of combination of B-cell maturation antigen and Cd19 chimeric antigen receptor T Cells in multiple myeloma. J Clin Oncol. 2022;40:2246–56. https://doi.org/10.1200/JCO.21.01676.